Vaccine Equity and Global Access

Low-income countries received COVID-19 vaccines an average of 4 to 6 months later than wealthy nations, sparking intense debate over patent waivers and WHO reform. This delay cost an estimated 1.5 million lives globally, according to an Airfinity study. Unlike the broader discussions of ingredient safety in Vaccine Ingredient Transparency, this debate centers on structural inequity rather than individual risk. Technology transfer and local manufacturing remain unresolved as the world prepares for future pandemics, with only 10% of people in low-income countries having received a booster dose compared to 70% in high-income nations.